Breaking News

CellQuest Launches Early Access Program for CosyNest Manufacturing Platform

The EAP will enable cell therapy developers to use the CosyNest to bring costs down and increase the production of CAR-T cells.

Author Image

By: Charlie Sternberg

Associate Editor

CellQuest, a developer and manufacturer of automated chimeric antigen receptor (CAR)-T cell production platforms and solutions, has launched its Early Access Program (EAP) to introduce the CosyNest manufacturing platform to cell therapy developers.   CosyNest, a closed manufacturing system, has been designed to dramatically increase the production of CAR-T cells per person, and per unit area.   After five years of R&D, CellQuest believes CosyNest is poised to broaden access to CAR-T ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters